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Introduction ReferencesSignificance	of	
Pathophysiology
• Pathology	plays	a	major	impact	in	how	to	screen	individuals	and	families
• Updated	recommendations	
• Old	screening	 tools	(Amsterdam	I,	Amsterdam	II,	 and	revised	Bethesda	guideline)	determined	 if	an	 individual	was	at	high	risk	for	LS	based	on	personal	and	 family	history
• Still	sometimes	used	but	these	tools	can	miss	patients	who	should	be	tested	for	LS
• Tumor-based	screening	protocols	better	 identify	those	with	LS	according	 to	the	CDC	(Mange	et	al.,	2015,	 p.	422)
• Experts	 recommend	 that	every	person	newly	diagnosed	with	CRC	or	endometrial	 cancer	be	screened	 for	LS,	 this	is	referred	 to	as	universal	screening	(Vindigni&	Kaz,	2016,	 p.	971)
• The	Lynch	Syndrome	 Screening	Network	 (LSSN)	created	 in	2011	promotes	universal	screening,	website	is	http://www.lynchscreening.net(Mange	et	al.,	2015,	 p.	421	 &	424)
• Figure	2	is	a	sample	algorithm	for	universal	CRC	screening	(Vindigni&	Kaz,	2016,	 figure	1)
• Testing	is	by	immunohistochemistry	(IHC),	which	determines	whether	or	not	the	 four	 types	of	repair	 genes	are	present	on	a	tissue	sample	(Shulman,	2015,	 p.	35)
• The	other	 form	of	testing	looks	for	microsatellite	instability	which	are	errors	 in	repetitive	DNA	sequences	(see	Figure	3)
• Testing	for	both	 IHC	and	MSI	reduces	 the	likelihood	of	missing	a	diagnosis	of	LS	
• If	LS	 is	positive,	recommendations	also	involve	screening	family	members	(Vindigni &	Kaz,	2016,	 p.	970)
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Figure	1.	Lynch	Syndrome	 compared	 to	sporadic	colorectal	cancer,	differences	in	mutations	 illustrated,	both	 leading	to	cancer
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Figure	2.	Universal	testing	algorithm	for	colorectal	cancer	
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Figure	3.	http://kintalk.org/whats-lynch-syndrome/diagnosing-lynch-syndrome/
• Lynch	Syndrome	 (LS)	 is	a	cancer	susceptibility	syndrome
• Formerly	known	as	Hereditary	Non-Polyposis	Colorectal	Cancer	Syndrome	(HNPCC)
• Autosomal	dominant	 inherited	 trait
• High	penetrance,	 due	 to	defects	in	repairing	base	mismatches	during	DNA	replication	(Shulman,	2015,	 p.	33)
• Significantly	more	susceptible	to	colorectal	(CRC),	 endometrial	and	many	other	 types	of	cancer
• 50%	 chance	of	inheritance	if	one	parent	affected
• Four	 genes	become	mutated,	 called	mismatch	repair	 (MMR)	genes,	these	mutations	can	 lead	to	replication	of	 cancer	causing	cells (Mange	et	al.,	2015,	 p.	421-2)
• New	recommendations	within	the	last	five	years	include	screening	for	LS	in	all	newly	diagnosed	CRCs
• Universal	screening	reduces	mortality	and	increases	surveillance	for	those	with	a	familial	history	of	LS	(Vindigni &	Kaz,	2016,	p.	975)
• CRC	 incidence	has	declined	in	the	Unites	States	due	 to	increased	screening	methods	including	occult	blood	 tests	and	colonoscopies	(Waneboet	al.,	2012,	 p.	822)
• CRC	 is	the	third	most	common	cancer	worldwide,	and	second	 leading	cause	of	cancer-related	death
• LS	accounts	for	1-3%	of	these	tumors	(Moreira	et	al.,	2012,	 p.	1555)
• Advancing	cancer	 technology	is	relevant	 to	advanced	practice	nursing
• Knowledge	of	current	recommendations	 is	essential	to	evidence	based	practice
• Mismatch	repair	mutation	(MMR)	occurs	 in	one	of	the	following	genes:	MLH1,	MSH2,	MSH6,	PMS2
• Mismatch	repair	corrects	DNA	replication	mistakes	
• Loss	of	function	 in	 the	MMR	gene	means	two	hits	must	occur,	one	hit	to	each	allele
• Germlinemutations	are	transmitted	 to	offspring
• Mutation	 leads	to	loss	of	original	function	or	expression,	which	leads	to	pathogenesis	(Liu	et	al.,	2016,	 p.	417-18)
• Errors	 accumulate	during	DNA	replication	easily	in	repetitive	sequences	of	DNA	called	microsatellites,	this	is	called	microsatellite	instability	(MSI)	or	 loss	of	MMR	protein	expression,	which	defines	LS	(Moreira	et	al.,	2012,	 p.	1556)
• See	difference	in	mutation	 type	for	LS	compared	 to	spontaneous	CRC	(Sinicrope,	2010,	 figure	1) Conclusions
• Treatment	depends	 on	cancer	location	and	metastasis
• Liver	metastasis	results	in	significant	mortality	(Wanebo et	al.,	2012,	 p.	834)
• Individuals	develop	cancer	at	an	earlier	age	than	sporadic	cancers,	average	age	of	onset	is	45	 (Liu,	Thompson,	Ward,	Hesson,	&	Sloane,	2016,	 p.	417)
• Colorectal	and	endometrial	 cancer	are	 the	two	main	cancers	seen,	but	LS	also	increases	risk	for	ovarian,	stomach,	small	intestine,	hepatobiliary tract,	upper	urinary	 tract,	brain,	 and	skin	cancers	(Ten	Broeke et	al.,	2015,	 p.	325)
• Signs	and	symptoms	vary	according	to	 the	type	of	cancer
• Cancer	 risks:
LS - 4-5%	CRC
LS	+ 20-60%	CRC
LS	- 2-3%	Endometrial	CA
LS	+ 20-60%	Endometrial	CA
• Important	 to	educate	and	guide	patients
• Emotional	burdens	are	associated	with	hereditary	cancer	and	associated	knowledge
• Psychological	effects	have	focused	on	 family	genetic	testing	and	screening	related	 to	Huntington’s	disease	and	the	BRCA1/2	gene	associated	with	breast	cancer	
• Most	studies	focus	on	 immediate	family	and	not	extended	 family
• Cancer	distress,	cancer	worry,	 and	depression	all	need	to	be	further	researched	when	considering	familial	genetic	testing	(Eliezer,	Hadley,	&	Koehly,	2014,	 p.	1293)
• Practice	with	empathy	and	awareness	to	empower	patients	and	decide	what	to	do	with	the	knowledge	they	are	able	to	uncover	 through	 genetic	testing
• Preventative	medicine	and	primary	prevention	 is	far	more	effective	than	tertiary	prevention	interventions,	and	 the	 information	behind	LS	allows	more	opportunities	 to	prevent	cancer	rather	 than	 treat
• Genetic	advances	will	continue	to	evolve	and	screening	recommendations	 for	 individuals	and	 families	will	continually	change
• Knowledge	is	power:	current	knowledge	must	be	used	 in	a	way	to	benefit	the	general	population
• Increasing	awareness	is	essential,	providers	must	be	informed	about	new	screening	guidelines
• LS	poses	a	significant	risk	for	developing	cancer	but	 screening	tools	are	causing	decline	in	colorectal	cancer	mortality	(Wanebo et	al.,	2012,	 p.	822)
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